Active	Status	Sponsor type	Region	Phase	Filter
1 Active 2 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
simmitecan / HaiHe Biopharma, Shanghai Inst. of Materia Medica
NCT03992911: Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma	Recruiting	2/3	336	RoW	Simmtecan, 5-FU and l-LV, FOLFSIM regimen, Toripalimab, JS001, Etoposide, Cisplatin, EP regimen, Etoposide, Carboplatin, EC regimen	Peking University	Neuroendocrine Carcinoma of the Bladder	06/22	06/23